- Home
- ETON vs MAIA Comparison
ETON vs MAIA Comparison
Compare ETON & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- MAIA
- Stock Information
- Founded
- ETON 2017
- MAIA 2018
- Country
- ETON United States
- MAIA United States
- Employees
- ETON N/A
- MAIA N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- MAIA Health Care
- Exchange
- ETON Nasdaq
- MAIA Nasdaq
- Market Cap
- ETON 388.3M
- MAIA 56.3M
- IPO Year
- ETON 2018
- MAIA 2022
- Fundamental
- Price
- ETON $17.56
- MAIA $1.61
- Analyst Decision
- ETON Strong Buy
- MAIA
- Analyst Count
- ETON 3
- MAIA 0
- Target Price
- ETON $29.67
- MAIA N/A
- AVG Volume (30 Days)
- ETON 209.1K
- MAIA 468.7K
- Earning Date
- ETON 11-11-2025
- MAIA 11-11-2025
- Dividend Yield
- ETON N/A
- MAIA N/A
- EPS Growth
- ETON N/A
- MAIA N/A
- EPS
- ETON N/A
- MAIA N/A
- Revenue
- ETON $58,181,000.00
- MAIA N/A
- Revenue This Year
- ETON $105.25
- MAIA N/A
- Revenue Next Year
- ETON $40.84
- MAIA N/A
- P/E Ratio
- ETON N/A
- MAIA N/A
- Revenue Growth
- ETON 85.40
- MAIA N/A
- 52 Week Low
- ETON $5.18
- MAIA $1.40
- 52 Week High
- ETON $21.48
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- ETON 57.62
- MAIA 50.48
- Support Level
- ETON $17.24
- MAIA $1.54
- Resistance Level
- ETON $18.52
- MAIA $1.78
- Average True Range (ATR)
- ETON 0.68
- MAIA 0.09
- MACD
- ETON -0.06
- MAIA 0.02
- Stochastic Oscillator
- ETON 47.54
- MAIA 45.31
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.